Retention in buprenorphine treatment is associated with improved HCV care outcomes

Brianna L. Norton, A. Beitin, M. Glenn, Joseph P. DeLuca, A. H. Litwin, Chinazo O. Cunningham

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Persons who inject drugs, most of whom are opioid dependent, comprise the majority of the HCV infected in the United States. As the national opioid epidemic unfolds, increasing numbers of people are entering the medical system to access treatment for opioid use disorder, specifically with buprenorphine. Yet little is known about HCV care in patients accessing buprenorphine-based opioid treatment. We sought to determine the HCV prevalence, cascade of care, and the association between patient characteristics and completion of HCV cascade of care milestones for patients initiating buprenorphine treatment. We reviewed electronic health records of all patients who initiated buprenorphine treatment at a primary-care clinic in the Bronx, NY between January 2009 and January 2014. Of the 390 patients who initiated buprenorphine treatment, 123 were confirmed to have chronic HCV infection. The only patient characteristic associated with achieving HCV care milestones was retention in opioid treatment. Patients retained (vs. not retained) in buprenorphine treatment were more likely to be referred for HCV specialty care (63.1% vs. 34.0%, p < 0.01), achieve an HCV-specific evaluation (40.8% vs. 21.3%, p < 0.05), be offered HCV treatment (22.4% vs. 8.5%, p < 0.05), and initiate HCV treatment (9.2% vs. 6.4%, p = 0.6). Given the current opioid epidemic in the US and the growing number of people receiving buprenorphine treatment, there is an unprecedented opportunity to access and treat persons with HCV, reducing HCV transmission, morbidity and mortality. Retention in opioid treatment may improve linkage and retention in HCV care; innovative models of care that integrate opioid drug treatment with HCV treatment are essential.

Original languageEnglish (US)
Pages (from-to)38-42
Number of pages5
JournalJournal of Substance Abuse Treatment
Volume75
DOIs
StatePublished - Apr 1 2017

Fingerprint

Buprenorphine
Opioid Analgesics
Therapeutics
Patient Care
Electronic Health Records
Pharmaceutical Preparations
Primary Health Care

Keywords

  • Buprenorphine
  • Cascade of care
  • Hepatitis C
  • Medication assisted treatment
  • Opioid use disorder

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Phychiatric Mental Health
  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

Retention in buprenorphine treatment is associated with improved HCV care outcomes. / Norton, Brianna L.; Beitin, A.; Glenn, M.; DeLuca, Joseph P.; Litwin, A. H.; Cunningham, Chinazo O.

In: Journal of Substance Abuse Treatment, Vol. 75, 01.04.2017, p. 38-42.

Research output: Contribution to journalArticle

@article{356eaea7d4c643fdbdb5221612d526e4,
title = "Retention in buprenorphine treatment is associated with improved HCV care outcomes",
abstract = "Persons who inject drugs, most of whom are opioid dependent, comprise the majority of the HCV infected in the United States. As the national opioid epidemic unfolds, increasing numbers of people are entering the medical system to access treatment for opioid use disorder, specifically with buprenorphine. Yet little is known about HCV care in patients accessing buprenorphine-based opioid treatment. We sought to determine the HCV prevalence, cascade of care, and the association between patient characteristics and completion of HCV cascade of care milestones for patients initiating buprenorphine treatment. We reviewed electronic health records of all patients who initiated buprenorphine treatment at a primary-care clinic in the Bronx, NY between January 2009 and January 2014. Of the 390 patients who initiated buprenorphine treatment, 123 were confirmed to have chronic HCV infection. The only patient characteristic associated with achieving HCV care milestones was retention in opioid treatment. Patients retained (vs. not retained) in buprenorphine treatment were more likely to be referred for HCV specialty care (63.1{\%} vs. 34.0{\%}, p < 0.01), achieve an HCV-specific evaluation (40.8{\%} vs. 21.3{\%}, p < 0.05), be offered HCV treatment (22.4{\%} vs. 8.5{\%}, p < 0.05), and initiate HCV treatment (9.2{\%} vs. 6.4{\%}, p = 0.6). Given the current opioid epidemic in the US and the growing number of people receiving buprenorphine treatment, there is an unprecedented opportunity to access and treat persons with HCV, reducing HCV transmission, morbidity and mortality. Retention in opioid treatment may improve linkage and retention in HCV care; innovative models of care that integrate opioid drug treatment with HCV treatment are essential.",
keywords = "Buprenorphine, Cascade of care, Hepatitis C, Medication assisted treatment, Opioid use disorder",
author = "Norton, {Brianna L.} and A. Beitin and M. Glenn and DeLuca, {Joseph P.} and Litwin, {A. H.} and Cunningham, {Chinazo O.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.jsat.2017.01.015",
language = "English (US)",
volume = "75",
pages = "38--42",
journal = "Journal of Substance Abuse Treatment",
issn = "0740-5472",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Retention in buprenorphine treatment is associated with improved HCV care outcomes

AU - Norton, Brianna L.

AU - Beitin, A.

AU - Glenn, M.

AU - DeLuca, Joseph P.

AU - Litwin, A. H.

AU - Cunningham, Chinazo O.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Persons who inject drugs, most of whom are opioid dependent, comprise the majority of the HCV infected in the United States. As the national opioid epidemic unfolds, increasing numbers of people are entering the medical system to access treatment for opioid use disorder, specifically with buprenorphine. Yet little is known about HCV care in patients accessing buprenorphine-based opioid treatment. We sought to determine the HCV prevalence, cascade of care, and the association between patient characteristics and completion of HCV cascade of care milestones for patients initiating buprenorphine treatment. We reviewed electronic health records of all patients who initiated buprenorphine treatment at a primary-care clinic in the Bronx, NY between January 2009 and January 2014. Of the 390 patients who initiated buprenorphine treatment, 123 were confirmed to have chronic HCV infection. The only patient characteristic associated with achieving HCV care milestones was retention in opioid treatment. Patients retained (vs. not retained) in buprenorphine treatment were more likely to be referred for HCV specialty care (63.1% vs. 34.0%, p < 0.01), achieve an HCV-specific evaluation (40.8% vs. 21.3%, p < 0.05), be offered HCV treatment (22.4% vs. 8.5%, p < 0.05), and initiate HCV treatment (9.2% vs. 6.4%, p = 0.6). Given the current opioid epidemic in the US and the growing number of people receiving buprenorphine treatment, there is an unprecedented opportunity to access and treat persons with HCV, reducing HCV transmission, morbidity and mortality. Retention in opioid treatment may improve linkage and retention in HCV care; innovative models of care that integrate opioid drug treatment with HCV treatment are essential.

AB - Persons who inject drugs, most of whom are opioid dependent, comprise the majority of the HCV infected in the United States. As the national opioid epidemic unfolds, increasing numbers of people are entering the medical system to access treatment for opioid use disorder, specifically with buprenorphine. Yet little is known about HCV care in patients accessing buprenorphine-based opioid treatment. We sought to determine the HCV prevalence, cascade of care, and the association between patient characteristics and completion of HCV cascade of care milestones for patients initiating buprenorphine treatment. We reviewed electronic health records of all patients who initiated buprenorphine treatment at a primary-care clinic in the Bronx, NY between January 2009 and January 2014. Of the 390 patients who initiated buprenorphine treatment, 123 were confirmed to have chronic HCV infection. The only patient characteristic associated with achieving HCV care milestones was retention in opioid treatment. Patients retained (vs. not retained) in buprenorphine treatment were more likely to be referred for HCV specialty care (63.1% vs. 34.0%, p < 0.01), achieve an HCV-specific evaluation (40.8% vs. 21.3%, p < 0.05), be offered HCV treatment (22.4% vs. 8.5%, p < 0.05), and initiate HCV treatment (9.2% vs. 6.4%, p = 0.6). Given the current opioid epidemic in the US and the growing number of people receiving buprenorphine treatment, there is an unprecedented opportunity to access and treat persons with HCV, reducing HCV transmission, morbidity and mortality. Retention in opioid treatment may improve linkage and retention in HCV care; innovative models of care that integrate opioid drug treatment with HCV treatment are essential.

KW - Buprenorphine

KW - Cascade of care

KW - Hepatitis C

KW - Medication assisted treatment

KW - Opioid use disorder

UR - http://www.scopus.com/inward/record.url?scp=85010871728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010871728&partnerID=8YFLogxK

U2 - 10.1016/j.jsat.2017.01.015

DO - 10.1016/j.jsat.2017.01.015

M3 - Article

VL - 75

SP - 38

EP - 42

JO - Journal of Substance Abuse Treatment

JF - Journal of Substance Abuse Treatment

SN - 0740-5472

ER -